Alice Pomponio is Managing Director of BrightEdge, the American Cancer Society’s philanthropic venture impact fund. Alice brings more than 25 years of experience in life sciences and public policy coupled with her passion for the American Cancer Society’s lifesaving mission as a patient advocate and volunteer leader. She is an expert in rare disease and precision oncology, disruptive technology adoption, and companion diagnostic/therapeutic co-development strategies with an eye toward value-based care. Prior to ACS BrightEdge she was an advisor at Red Sky Partners LLC and the founder and managing director of Accendo. At Red Sky Partners, Alice advised high-growth life sciences and health tech companies on go-to-market and product value strategies. In 2018, she founded Accendo to accelerate entrepreneurial consumer-facing approaches to patient access and affordability of quality care. She previously held strategy and operational leadership roles at Radius Health, AstraZeneca, and Sanofi Genzyme, where she launched multiple US and global specialty products and championed orphan drug and health equity initiatives across the globe. Her public sector experience spans innovation, trade, and healthcare policy through roles in the UK Government and US Office of Management and Budget. Alice holds a Master of Public Policy from Harvard University and a Bachelor of Science in Biology from MIT. She serves on the boards of Massachusetts Biotechnology Council, MassEcon, and PhagePro Inc. Additionally, she teaches entrepreneurship as a faculty member of Harvard-MIT HST Sloan Healthcare Ventures and MIT Catalyst where she focuses on patient-centric impact innovation.

Dr. José Trevejo is a physician-scientist and an infectious disease specialist who has spent his career pursuing his passion for leading research and development teams in the advancement of novel therapeutics for serious diseases. Prior to his current role as Chief Development Officer at Rocket Pharma, he was CEO at SmartPharm Therapeutics that is currently developing novel countermeasures for COVID-19. Prior to SmartPharm, Dr. Trevejo served as Vice President, Clinical Development at Cyclerion Therapeutics. Dr. Trevejo joined Ironwood/Cyclerion from Visterra, where he was a member of the Executive Team and lead the pre-clinical and clinical development of novel biologics for infectious diseases. While at Visterra he oversaw the transition to a clinical stage company as well as helped to secure a $215 million DHHS award to support development of a novel treatment for influenza. Prior to Visterra, he held clinical development leadership positions at Genentech and Vertex Pharmaceuticals. Before entering the biotechnology industry, he served as Instructor in Medicine at Harvard Medical School and was a Principal Biomedical Scientist at the Draper Laboratory working on novel diagnostics for tuberculosis and other infectious diseases. Dr. Trevejo completed his clinical training at BWH/BIDMC/Harvard Medical School and earned his M.D. and Ph.D. from the Tri-Institutional MD-PhD program at Cornell-Rockefeller-Sloan Kettering in New York.

Kenneth Turner is President & CEO of the Massachusetts Life Sciences Center (MLSC), an economic development and investment agency dedicated to supporting the growth and development of the life sciences in Massachusetts. He directs and oversees the center's operations, investment strategy, programs, and partnerships. Prior to joining the MLSC, Mr. Turner serves as Director of Diversity & Inclusion/Compliance with Massport. He oversaw and managed the Authority's multiple diversity programs, including business and supplier diversity, workforce diversity, and airport concessions, as well as compliance initiatives with Massport's Disadvantaged/Minority/Women Business Enterprise programs. Previously, Mr. Turner serves as Deputy Secretary for Administration & Finance for the Commonwealth of Massachusetts Department of Veterans' Services. He has over 20-years of general management and executive experience in various Fortune 100 media and package good companies including having served as Senior Vice President of Emerging Markets at AOL Time Warner as well a having held various positions at Hallmark Cards and Hasbro Toys. A retired U.S Navy Captain and submarine nuclear weapons system officer with 26-years of service. Mr. Turner holds a B.S degree in Liberal Arts from Southern University and A&M College, Baton Rouge, LA.